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Executive summary 
The goal of our proposed research is to construct a three dimensional (3D) human prostate 
cancer tissue in vitro for the study of cancer biology and rapid screening of anti-cancer drugs. 
The specific aims of this research are: 
1. Fabricate tissue engineering scaffolds for 3D culture of human prostate cancers 
2. Build 3D models of human prostate cancer in vitro 
3. Characterize the 3D prostate cancer models at cellular and molecular levels 
In the first stage of the project, we have made significant progress in Aims 1 and 2 (see the first 
progress report). In the past year, we have made significant progress towards all 3 specific aims. 
We have 1. tested the constructs in a perfusion system; 2. evaluated the culture of endothelial 
cells, and 3. built tubular scaffolds to better mimic in vivo tumor development. From these results 
we concluded that 1. in order to mimic the in vivo cancer development and build a true 3D model 
in vitro, perfusion is needed; 2. prostate cancer cells will not withstand the shear stress of direct 
perfusion, thus co-culture with endothelial cells will be needed; and 3. a tubular scaffold with an 
endothelialized lumen and cancer cells grow in the pores around the endothelialized tube will 
best mimic the physiological conditions. We have submitted part of the results reported in the 
last and this progress report for publication in the Journal of Biomedical Materials Research in 
November 2006. The financial support of GCC was acknowledged in the manuscript. We plan to 
submit a R21 application to NCI in March 2007. 
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I. 3D C u l t u r e of H u m a n P r o s t a t e C a n c e r Cells u n d e r Perfusion 
In order to increase the size of the 3D cancer constructs, we perfused the constructs with 
culture medium to increase the delivery of nutrients and removal of wastes. The perfusion did 
not alter the overall morphology of the LNCaP cells, however, no increase in cell cluster size 
was observed (Fig. 1 A). In fact, the cell number was lower than those of the static culture, this 
was likely caused by the detachment of LNCaP cells due to increase shear stress (Fig. 1 B). 
Indeed, floating cells were observed in the circulating medium. Thus we decided to use 
endothelial cells to shield the cancer cells from shear stress as is the case for in vivo systems. 
Fig. 1. (A) SEM micrograph of the cross-section of a perfused construct based on LNCaP Cells 
and PGS scaffolds. (B) M T T assay of LNCaP cells grown on scaffolds under constant perfusion. 
The cell number was lower than static culture conditions. 
This new fabrication process allowed us to produce PGS scaffolds with controlled pore size, 
porosity, and well interconnected pores. The porosity and pore size of scaffolds can be easily 
controlled by the ratio of salt and PGS, and salt particle sizes. This process has three advantages. 
First, the scaffold has homogeneous distribution of pores and polymer, which is more suitable for 
culturing cells in three dimensions. Second, micropores in the walls of the micropores increases 
interconnectivity of the pores and are beneficial to cell-cell communication, cell interaction, and 
mass transport. Third, the scaffold can be directly fabricated into specific shape with mold. 
II. Endothe l ia l iza t ion of the P G S Scaffolds 
To investigate the feasibility of endothelialize PGS scaffolds, we cultured primary endothelial 
cells (ECs) on PGS surfaces. The results indicated that EC can adhere and proliferate well on 
PGS, and the cell phenotype is well maintained as shown by the positive vWF-staining (Fig. 2). 
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Fig. 2. The proliferation of primary endothelial 
cells on PGS was similar to that on TCPS. (A) The 
number of metabolically active cells was indicated 
by the absorption of M T T at 570 nm. (B) ECs 
(PI4) cultured on PGS-coated cover slips exhibited 
typical cobblestone morphology. 160X; scale bar 
= 200 |um. (C) the ECs expressed vWF (red) in 
cytoplasmic granules on PGS surface, 200x, scale 
bar = 200 urn. 
III. Fab r i ca t i on of t u b u l a r P G S Scaffolds 
To explore coculture of ECs and LNCaP cells, we redesigned our approach to use PGS 
tubular scaffolds. The plan is to first endothelialize the lumen of the tube, then LNCaP cells will 
be seeded in the pores of the wall. This shields the tumor cells from direct shear stress while 
enhancing the nutrient delivery and waste removal mimicking the in vivo tumor development. 
We have successfully fabricated PGS tubular scaffold using a strategy illustrated in Fig. 3. the 
use of heat-shrink tubing as a mandrel is necessary as we found the mandrel removal to be 
extremely challenging with conventional Teflon mandrel due to the large aspect ratio. 
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Fig. 3. The fabrication of the seamless tubular PGS scaffold succeeded after numerous iteration. 
The six sub-figures depicts 1. the Teflon mold with a heat-shrink tubing as the mandrel; 2. the 
salt template that is removed from the outer-mold; 3. the free hanging salt template after the 
mandrel was shrunk at 150 °C; 4. PGS solution was added to the salt template; 5. PGS was cured 
at 150 °C, and salt template was dissolved in water; and 6. the dry scaffold after water removal 
by lyophilization. 
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F I N A L R E P O R T on W h i t a k e r F o u n d a t i o n sponsored r e sea r ch pro jec t (TF-03-0021) 
Quan t i t a t i ve Analysis of T a r g e t e d R e t r o v i r u s Infect ion (PI : J o s e p h M . L e Doux , P h D ) 
I. A B S T R A C T 
W h y the p ro jec t was u n d e r t a k e n 
Recombinant retroviruses are one of the most commonly used means to transfer genes in gene 
therapy clinical trials because they can permanently integrate a therapeutic gene into the 
chromosomal D N A of target cells, resulting, in principle, in a long-term cure. Unfortunately, the 
current generation of recombinant retroviruses often are not able to both efficiently and 
selectively transfer genes to cells. Given the large number of important clinical applications, 
there is significant motivation to improve the efficiency and selectivity of retroviral-mediated 
gene transfer. Successful gene transfer with retroviruses requires the completion of a complex 
series of steps that begins with binding of the virus to the cell, transport of the bound virus to a 
location where its cellular receptors are expressed, followed by an interaction between the 
envelope proteins of the virus and their cellular receptors that leads to fusion of the virus with the 
cell and its entry into the cytoplasm. The mechanisms by which these steps of infection occur 
are poorly understood. It is important that we understand the mechanism by which retroviruses 
accomplish these early steps of infection because such knowledge could lead to the development 
of more efficient and selective strategies for genetically modifying cells in human gene therapy 
protocols, or for blocking infection by wild-type, pathogenic retroviruses. Therefore we 
undertook the Whitaker project in order to make progress towards our long-term goal, which is 
to establish engineering-based strategies for improving the functionality of recombinant 
retroviruses and lentiviruses for the purposes of human gene therapy. 
W h a t r e sea rch was p e r f o r m e d 
We had two major findings. First, we found that the route that retroviruses take within a cell is 
controlled by the receptors and co-receptors that they interact with when they bind to the cells 
they are infecting. In addition, the probability that they will successfully infect a cell is a 
function of the intracellular pathway they take. We showed this be developing a novel 
experimental system that was composed of several cell lines that expressed retrovirus receptors 
that were identical in the portion that interacts with viruses, but different in the portion that 
controlled how the receptors were trafficked within the cell. W e engineered retroviruses to bind 
to these receptors, and studied the effect of receptor trafficking on virus trafficking and infection. 
Our second major finding was that retroviruses activate intracellular signals when they bind to 
cells. Specifically, they activate r ac l , a molecule that coordinates the formation of actin 
filaments within the cells. We showed that viruses induce this signaling via proteoglycans on the 
surface of the virus and via integrins on the surfaces of the cells. We are currently investigating 
the role that racl activation has in retrovirus transduction. 
W h y the pro jec t was i m p o r t a n t 
The project was important because it showed that the molecules that are on the surface of 
retroviruses dictate how the viruses will traffick within the cell, and whether or not they induce 
intracellular signaling. Our findings suggest that by manipulating the surface properties of 
retroviruses, we should be able to control the signals they induce within cells, and how the 
viruses are transported within the cells, and thereby control the outcome of gene transfer, either 
making it more efficient, more selective, or both. The ability to do this will enable us to develop 
safer, more effective human gene therapy protocols. 
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III. G R A N T S 
Con t inu ing s u p p o r t for W h i t a k e r pro jec t 
None, but I am currently preparing an R01 that is based on the Whitaker project data. 
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